The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Computational pathology to predict docetaxel benefit in patients with metastatic hormone-sensitive prostate cancer from the CHAARTED trial (ECOG-ACRIN E3805).
 
Sebastian Medina
No Relationships to Disclose
 
Naoto Tokuyama
No Relationships to Disclose
 
Kamal Hammouda
No Relationships to Disclose
 
Tilak Pathak
No Relationships to Disclose
 
Tuomas Mirtti
No Relationships to Disclose
 
Pingfu Fu
No Relationships to Disclose
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Priti Lal
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; CellCentric; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Anant Madabhushi
Employment - Picture Health; Picture Health
Leadership - Inspirata; Picture Health
Stock and Other Ownership Interests - Elucid Bioimaging; Inspirata; Picture Health
Honoraria - AstraZeneca; Inspirata
Consulting or Advisory Role - Aiforia; Caris Life Sciences; Castle Biosciences; Cernostics; Merck; Roche; SimBioSys
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers-Squibb (Inst); Inspirata (Inst); Philips Healthcare (Inst)
Patents, Royalties, Other Intellectual Property - IP Licensed by Elucid Bioimaging (Inst); IP licensed by Inspirata Inc. (Inst); Technologies licensed from Case Western Reserve University to Picture Health